Research programme: influenza monoclonal antibodies - Crucell

Drug Profile

Research programme: influenza monoclonal antibodies - Crucell

Alternative Names: CR 8043; CR-8033; CR-8071; CR-9114; flu-mAb; flumab; H5N1 virus antibodies - Crucell; Pandemic influenza antibodies - Crucell

Latest Information Update: 03 Dec 2012

Price : $50

At a glance

  • Originator AIMM Therapeutics; Crucell
  • Developer Crucell
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 03 Dec 2012 Janssen licenses the NanoPass MicronJet®, microneedle delivery device for use in its (Crucell's) influenza vaccine programmes
  • 10 Aug 2012 Pharmacodynamics data from a preclinical trial in Influenza virus infections released by Crucell
  • 16 Aug 2011 Preclinical development is ongoing in the Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top